Evaluating fulvestrant-resistance in HCC1428 breast cancer cells
Overcoming drug resistance in breast cancer Breast cancer remains the most common malignancy in women worldwide with over 2 million newly diagnosed cases in 2018, accounting for almost a quarter of all cancer cases in women. More than 70% of breast tumors depend on estrogen for survival and growth, which led to the development of targeted therapy against the associated cellular hormone receptor